A Phase 1, Double-blind, Placebo-controlled, First-in-human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ABBV-1042 in Healthy Subjects
Latest Information Update: 04 Nov 2025
At a glance
- Drugs ABBV 1042 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
Most Recent Events
- 04 Nov 2025 New trial record